Astrana Health, Inc. (NASDAQ:ASTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $53.29.

Several analysts recently issued reports on the stock. Robert W. Baird cut their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Truist Financial cut their price objective on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Bank of America reduced their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus lowered their target price on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Finally, Barclays began coverage on Astrana Health in a research report on Tuesday, April 1st. They issued an “equal weight” rating and a $36.00 price target for the company.

Astrana Health Price Performance

NASDAQ ASTH opened at $31.38 on Monday. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.37 and a beta of 1.04. Astrana Health has a 1-year low of $23.12 and a 1-year high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The business’s fifty day moving average price is $32.01 and its 200-day moving average price is $39.03.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. On average, equities analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Trading of Astrana Health

Several institutional investors have recently made changes to their positions in the business. City Center Advisors LLC bought a new position in Astrana Health in the 1st quarter worth approximately $276,000. E. Ohman J or Asset Management AB lifted its holdings in shares of Astrana Health by 85.8% in the first quarter. E. Ohman J or Asset Management AB now owns 61,300 shares of the company’s stock worth $1,901,000 after buying an additional 28,300 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Astrana Health by 5,794.8% during the first quarter. GAMMA Investing LLC now owns 12,497 shares of the company’s stock worth $403,000 after acquiring an additional 12,285 shares during the last quarter. PharVision Advisers LLC purchased a new position in Astrana Health during the fourth quarter valued at $211,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Astrana Health by 15.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,658 shares of the company’s stock valued at $3,300,000 after acquiring an additional 14,138 shares during the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.